NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
AbCellera Biologics Inc. ABCL
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$75.1M
▲ 160.6% vs FY2024
EPS · FY25
$-0.49
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-14.5%
Net margin · FY25
-194.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 75.1M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 195 cents on every revenue dollar this year.
Per share
USD -0.49
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-14.5%
Return on equity, FY2025
ROE
Operating margin-289.0%
Net margin-194.9%
Return on assets-10.8%
Each USD of equity lost 14 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−20.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−46.3%
−20.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.30B
Shares outstanding, FY2025
Change, 5 years+11.5%
Change, 10 years—
The share count grew 12% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD 966.9M
CashUSD 128.5M
Current ratio11.32×
Equity funds 71% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.0
0.0
0.5
0.4
0.2
0.0
Operating income $B
−0.2
−0.3
−0.2
0.2
0.2
0.2
−0.0
EBITDA $B
−0.2
−0.3
−0.2
0.2
0.2
0.2
−0.0
Income tax $B
−0.0
−0.0
−0.0
0.1
0.1
0.0
·
Net income $B
−0.1
−0.2
−0.1
0.2
0.2
0.1
−0.0
EPS, diluted $
−0.49
−0.55
−0.51
0.50
0.48
0.45
−0.01
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−14.5
−14.7
−12.3
14.0
16.5
28.3
−21.6
Shares out B
0.30
0.30
0.29
0.29
0.28
0.27
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed